Citations

Mayo Clinic

Showing 10 of 108585 citations.

Current State of Functional MRI in the Presurgical Planning of Brain Tumors
Lakhani, Dhairya A. , Sabsevitz, David S. , Chaichana, Kaisorn L. , Quiñones‐Hinojosa, Alfredo , Middlebrooks, Erik H. , Middlebrooks, Erik H , Lakhani, Dhairya

Radiology: Imaging Cancer | October 20, 2023 | Volume: 5 | Issue: 6 | Pages: No page available

10.1148/rycan.230078 | PMID 37861422 Get It

An APRI+ALBI-Based Multivariable Model as a Preoperative Predictor for Posthepatectomy Liver Failure
Santol, Jonas , Gregory, Lindsey A., Baumgartner, Ruth , Birgin, Emrullah , Gloor, Severin , Braunwarth, Eva , Ammann, M. , Starlinger, Johannes , Ammon, Daphni , Ninkovic, Marijana , Kern, Anna , Rumpf, Benedikt , Ortmayr, Gregor , Herrmann, Yannic, Huber, Felix Xaver, Weninger, Jeremias, Smoot, Rory L. , Truty, Mark J. , Kendrick, Michael L. , Nagorney, David M. , Rahbari, Nuh N. , Hoffmann, Katrin , Hackl, Hubert , Maier, Eva , Smoot, Rory L , Hackl, Hubert , Santol, Jonas , Ammann, Markus , Kim, Sarang , Murtha-Lemekhova, Anastasia , Pereyra, David , Kern, Anna E., Dong, Yawen , Thiels, Cornelius A. , Warner, Susanne G. , Cleary, Sean P. , Beldi, Guido , Gilg, Stefan , Assinger, Alice , Gruenberger, Thomas , Starlinger, Patrick

Annals of Surgery | October 20, 2023 | Volume: 281 | Issue: 5 | Pages: 861-871

10.1097/sla.0000000000006127 | PMID 37860868 Get It

Objective and Background: Clinically significant posthepatectomy liver failure (PHLF B+C) remains the main cause of mortality after major hepatic resection. This study aimed to establish an aspartate aminotransferase to platelet ratio combined with an albumin-bilirubin grade (APRI+ALBI), based multivariable model (MVM) to predict PHLF and compare its performance to indocyanine green clearance (ICG-R15 or ICG-PDR) and albumin-ICG evaluation (ALICE). Methods: A total of 12,056 patients from the National Surgical Quality Improvement Program database were used to generate a MVM to predict PHLF B+C. The model was determined using stepwise backwards elimination. The performance of the model was tested using receiver operating characteristic curve analysis and validated in an international cohort of 2525 patients. In 620 patients, the APRI+ALBI MVM, trained in the National Surgical Quality Improvement Program cohort, was compared with the MVM’s based on other liver function tests (ICG clearance, ALICE) by comparing the areas under the curve (AUC). Results: A MVM including APRI+ALBI, age, sex, tumor type, and extent of resection was found to predict PHLF B+C with an AUC of 0.77, with comparable performance in the validation cohort (AUC: 0.74). In direct comparison with other MVM’s based on more expensive and time-consuming liver function tests (ICG clearance, ALICE), the APRI+ALBI MVM demonstrated equal predictive potential for PHLF B+C. A smartphone application for the calculation of the APRI+ALBI MVM was designed. Conclusion: Risk assessment through the APRI+ALBI MVM for PHLF B+C increases preoperative predictive accuracy and represents a universally available and cost-effective risk assessment before hepatectomy, facilitated by a freely available smartphone app.
Toxicities of CAR T-cell therapy: a review of current literature
Shah, Syed Muhammad Ismail , Rani, Anooja , Kazmi, Sana , Savul, Ilma Saleh , Ukrani, Janta, Khan, Farmanullah , Hasan, Chaudhary A., Rathore, Navin, Syed, Maria , Keswani, Shiwani, Surkasha, FNU, Mal, Doongro, Kumar, Dileep , Asghar, Muhammad Sohaib

Annals of Medicine & Surgery | October 20, 2023 | Volume: 85 | Issue: 12 | Pages: 6013-6020

10.1097/ms9.0000000000001375 | PMID 38098580 Get It

The chimeric antigen receptor (CAR) design, first invented by Zelig Eshhar, paved the way for the use of genetically modified T-cells in targeted therapy against cancer cells. Since then, it has gone through many generations, especially with the integration of co-stimulation in the second and third-generation CARs. However, it also mounts a hyperactive immune response named as cytokine release syndrome with the release of several cytokines eventually resulting in multiple end-organ toxicities. The severity of cytokine release syndrome depends upon certain factors such as the tumor burden, choice of co-stimulation, and degree of lymphodepletion, and can manifest as pulmonary edema, vascular leak, renal dysfunction, cardiac problems, hepatic failure, and coagulopathy. Many grading criteria have been used to define these clinical manifestations but they lack harmonization. Neurotoxicity has also been significantly associated with CAR T-cell therapy but it has not been studied much in previous literature. This review aims to provide a comprehensive account of the clinical manifestations, diagnosis, management, and treatment of CAR T-cell associated neurotoxicity.
Digital health utilities in acute kidney injury management
Kashani, Kianoush , Koyner, Jay L.

Current Opinion in Critical Care | October 20, 2023 | Volume: 29 | Issue: 6 | Pages: 542-550

10.1097/mcc.0000000000001105 | PMID 37861196 Get It

Purpose of review Acute kidney injury (AKI) is a highly prevalent clinical syndrome that substantially impacts patient outcomes. It is accepted by the clinical communities that the management of AKI is time-sensitive. Unfortunately, despite growing proof of its preventability, AKI management remains suboptimal in community, acute care, and postacute care settings. Digital health solutions comprise various tools and models to improve care processes and patient outcomes in multiple medical fields. AKI development, progression, recovery, or lack thereof, offers tremendous opportunities for developing, validating, and implementing digital health solutions in multiple settings. This article will review the definitions and components of digital health, the characteristics of AKI that allow digital health solutions to be considered, and the opportunities and threats in implementing these solutions. Recent findings Over the past two decades, the academic output related to the use of digital health solutions in AKI has exponentially grown. While this indicates the growing interest in the topic, most topics are primarily related to clinical decision support by detecting AKI within hospitals or using artificial intelligence or machine learning technologies to predict AKI within acute care settings. However, recently, projects to assess the impact of digital health solutions in more complex scenarios, for example, managing nephrotoxins among adults of pediatric patients who already have AKI, is increasing. Depending on the type of patients, chosen digital health solution intervention, comparator groups, and selected outcomes, some of these studies showed benefits, while some did not indicate additional gain in care processes or clinical outcomes. Summary Careful needs assessment, selection of the correct digital health solution, and appropriate clinical validation of the benefits while avoiding additional health disparities are moral, professional, and ethical obligations for all individuals using these healthcare tools, including clinicians, data scientists, and administrators.
Verification and Validation of Lower Body Negative Pressure as a Non-Invasive Bioengineering Tool for Testing Technologies for Monitoring Human Hemorrhage
Convertino, Víctor A. , Snider, Eric J. , Collier, James P., Eaton, Samantha K. , Holmes, David R. , Haider, Clifton R. , Salinas, José , Torres, Sofía I. Hernández , Holmes, David R.

Bioengineering | October 20, 2023 | Volume: 10 | Issue: 10 | Pages: 1226

10.3390/bioengineering10101226 | PMID 37892956 Get It

Since hemorrhage is a leading cause of preventable death in both civilian and military settings, the development of advanced decision support monitoring capabilities is necessary to promote improved clinical outcomes. The emergence of lower body negative pressure (LBNP) has provided a bioengineering technology for inducing progressive reductions in central blood volume shown to be accurate as a model for the study of the early compensatory stages of hemorrhage. In this context, the specific aim of this study was to provide for the first time a systematic technical evaluation to meet a commonly accepted engineering standard based on the FDA-recognized Standard for Assessing Credibility of Modeling through Verification and Validation (V&V) for Medical Devices (ASME standard V&V 40) specifically highlighting LBNP as a valuable resource for the safe study of hemorrhage physiology in humans. As an experimental tool, evidence is presented that LBNP is credible, repeatable, and validated as an analog for the study of human hemorrhage physiology compared to actual blood loss. The LBNP tool can promote the testing and development of advanced monitoring algorithms and evaluating wearable sensors with the goal of improving clinical outcomes during use in emergency medical settings.
Perspectives on Musical Care Throughout the Life Course: Introducing the Musical Care International Network
Spiro, Neta , McConnell, Bonnie B. , Pike, Georgia , Baraldi, Filippo Bonini , Buren, Kathleen Van, Camlin, Dave, Cardoso, Tânya Marques , Çifdalöz, Burçin Uçaner, Dumbauld, Ben, Ettenberger, Mark , Fouché, Sunelle , Frid, Emma , Gosine, Jane, graham-jackson, april l., Grahn, Jessica A. , Harrison, Klisala , Mollison, Sally, Morrison, Steven J. , Pérez-Acosta, Gabriela , Pitt, Jessica , Robledo, Juan-Pablo , Roginsky, Efrat , Shaughnessy, Caitlin , Sunderland, Naomi , Talmage, Alison , Tsiris, Giorgos , Wit, Krista de , Sanfilippo, Katie Rose M. , Mori, Bernd Brabec de , Cross, Ian R.M. , Dumbauld, Ben, Hansen, Kjetil Falkenberg , Ilari, Beatriz Senoi , Perkins, Rosie , Rabinowitch, Tal-Chen

Music & Science | October 20, 2023 | Volume: 6 | Issue: No issue available | Pages: No page available

10.1177/20592043231200553 Get It

In this paper we report on the inaugural meetings of the Musical Care International Network held online in 2022. The term “musical care” is defined by Spiro and Sanfilippo (2022) as “the role of music—music listening as well as music-making—in supporting any aspect of people's developmental or health needs” (pp. 2–3). Musical care takes varied forms in different cultural contexts and involves people from different disciplines and areas of expertise. Therefore, the Musical Care International Network takes an interdisciplinary and international approach and aims to better reflect the disciplinary, geographic, and cultural diversity relevant to musical care. Forty-two delegates participated in 5 inaugural meetings over 2 days, representing 24 countries and numerous disciplines and areas of practice. Based on the meetings, the aims of this paper are to (1) better understand the diverse practices, applications, contexts, and impacts of musical care around the globe and (2) introduce the Musical Care International Network. Transcriptions of the recordings, alongside notes taken by the hosts, were used to summarise the conversations. The discussions developed ideas in three areas: (a) musical care as context-dependent and social, (b) musical care's position within the broader research and practice context, and (c) debates about the impact of and evidence for musical care. We can conclude that musical care refers to context-dependent and social phenomena. The term musical care was seen as useful in talking across boundaries while not minimizing individual disciplinary and professional expertise. The use of the term was seen to help balance the importance and place of multiple disciplines, with a role to play in the development of a collective identity. This collective identity was seen as important in advocacy and in helping to shape policy. The paper closes with proposed future directions for the network and its emerging mission statement.
In Search of the “Best Test”
Green, Isabel C.

Obstetrics & Gynecology | October 19, 2023 | Volume: 142 | Issue: 5 | Pages: 1017-1018

10.1097/aog.0000000000005408 | PMID 37856852 Get It

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
Augustin, Ryan C. , Newman, Sarah, Li, Aofei, Joy, Marion , Lyons, Maureen A. , Pham, Mary P, Smith, Katelyn, Isett, Brian R. , Najjar, Yana G. , Zarour, Hassane M. , Luke, Jason J. , Bao, Riyue , Davar, Diwakar , Najjar, Yana G , Luke, Jason J , Bao, Riyue , Pham, Mary P, Lucas, Peter C. , Sander, Cindy , Davar, Diwakar , Kirkwood, John M.

Journal for ImmunoTherapy of Cancer | October 19, 2023 | Volume: 11 | Issue: 10 | Pages: e007567

10.1136/jitc-2023-007567 | PMID 37857525 Get It

Acral melanoma (AM) has distinct characteristics as compared with cutaneous melanoma and exhibits poor response to immune checkpoint inhibitors (ICIs). Tumor-intrinsic mechanisms of immune exclusion have been identified in many cancers but less studied in AM. We characterized clinically annotated tumors from patients diagnosed with AM at our institution in correlation with ICI response using whole transcriptome RNAseq, whole exome sequencing, CD8 immunohistochemistry, and multispectral immunofluorescence imaging. A defined interferon-γ-associated T cell-inflamed gene signature was used to categorize tumors into non-T cell-inflamed and T cell-inflamed phenotypes. In combination with AM tumors from two published studies, we systematically assessed the immune landscape of AM and detected differential gene expression and pathway activation in a non-T cell-inflamed tumor microenvironment (TME). Two single-cell(sc) RNAseq AM cohorts and 11 bulk RNAseq cohorts of various tumor types were used for independent validation on pathways associated with lack of ICI response. In total, 892 specimens were included in this study. 72.5% of AM tumors showed low expression of the T cell-inflamed gene signature, with 23.9% of total tumors categorized as the non-T cell-inflamed phenotype. Patients of low CD3 + CD8 + PD1 + intratumoral T cell density showed poor prognosis. We identified 11 oncogenic pathways significantly upregulated in non-T cell-inflamed relative to T cell-inflamed TME shared across all three acral cohorts (MYC, HGF, MITF, VEGF, EGFR, SP1, ERBB2, TFEB, SREBF1, SOX2, and CCND1). scRNAseq analysis revealed that tumor cell-expressing pathway scores were significantly higher in low versus high T cell-infiltrated AM tumors. We further demonstrated that the 11 pathways were enriched in ICI non-responders compared with responders across cancers, including AM, cutaneous melanoma, triple-negative breast cancer, and non-small cell lung cancer. Pathway activation was associated with low expression of interferon stimulated genes, suggesting suppression of antigen presentation. Across the 11 pathways, fatty acid synthase and CXCL8 were unifying downstream target molecules suggesting potential nodes for therapeutic intervention. A unique set of pathways is associated with immune exclusion and ICI resistance in AM. These data may inform immunotherapy combinations for immediate clinical translation.
Variations in Administrative Approvals During the COVID-19 Pandemic at Participating Sites in the Society of Critical Care Medicine Discovery Network Viral Infection and Respiratory Illness Universal Study: COVID-19 Registry: A Cross-Sectional Study
Bansal, Vikas , Sharma, Mayank , Qamar, Shahraz , Lyman, Susan K., Kumar, Vishakha K. , Bogojevic, Marija , Nawathe, Pooja , Boman, Karen , Retford, Lynn, Group, for the Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator, Tawheed, Ahmed , Lyman, Susan, Singh, Romil , Bansal, Vikas , Deo, Neha , Walkey, Allan J. , Tekin, Aysun , Gajic, Ognjen , Kashyap, Rahul , Group, for the Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator

Critical Care Explorations | October 19, 2023 | Volume: 4 | Issue: 12 | Pages: e0822

10.1097/cce.0000000000000822 | PMID 36567789 Get It

OBJECTIVES: There is a paucity of literature regarding administrative approvals required for clinical studies during a pandemic. We aimed to evaluate variation in duration of administrative approvals within the Viral Infection and Respiratory illness Universal Study (VIRUS): A Global COVID-19 Registry. DESIGN, SETTING, AND SUBJECTS: Survey analysis of 188 investigators who participated in the VIRUS: COVID-19 registry, a prospective, observational global registry database of 287 sites. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: For each study site approved through December 8, 2020, we assessed the duration in days: 1) from institutional review board (IRB) submission to IRB approval, 2) from IRB approval to Research Electronic Data Capture (REDCap) access, 3) from REDCap access to first patient data entry in REDCap, and 4) total duration from IRB submission to first patient data entry in REDCap. Analysis of variance and Wilcoxon rank-sum test were used to compare time durations. Of 287 sites, 188 sites (United States = 155, non-United States = 33) provided complete administrative data. There was considerable variability in duration from IRB submission to first patient data entry with median (interquartile range) of 28 days (16–50 d), with differences not significantly different by country (United States: 30 [17–50] vs non-United States: 23 d [8–46 d]; p = 0.08) or previous “multisite trial experience” (experienced: 27 [15–51] vs not experienced: 29 d [13–47 d]; p = 0.67). The U.S. sites had a higher proportion of female principal investigators (n = 77; 50%), compared with non-U.S. sites (n = 7; 21%; p = 0.002). Non-U.S. sites had a significantly shorter time to first patient data entry after REDCap access: 7 (1–28) versus 3 days (1–6 d) (p = 0.02). CONCLUSIONS: In this Society of Critical Care Medicine global VIRUS: COVID-19 Registry, we identified considerable variability in time from IRB submission to first patient data entry with no significant differences by country or prior multicenter trial experience. However, there was a significant difference between US and non-U.S. sites in the time from REDCap access to first data entry.
MicroRNA Expression Profile in Early-Stage Breast Cancers
Patel, Krishna , Rao, Deva Magendhra , Sundersingh, Shirley , Sridevi, Velusami , Rajkumar, Thangarajan , Nair, B J Bipin , Pandey, Akhilesh , Chatterjee, Aditi , Mani, Samson , Gowda, Harsha , Rao, Arunagiri Kuha Deva Magendhra , Nair, Bipin , Pandey, Akhilesh , Gowda, Harsha

MicroRNA | October 19, 2023 | Volume: 13 | Issue: 1 | Pages: 71-81

10.2174/0122115366256479231003064842 | PMID 37873952 Get It

Background:: Breast cancer is one of the leading causes of cancer deaths in women. Early diagnosis offers the best hope for a cure. Ductal carcinoma in situ is considered a precursor of invasive ductal carcinoma of the breast. In this study, we carried out microRNA sequencing from 7 ductal carcinoma in situ (DCIS), 6 infiltrating ductal carcinomas (IDC Stage IIA) with paired normal, and 5 unpaired normal breast tissue samples. We identified 76 miRNAs that were differentially expressed in DCIS and IDC. Methods:: Additionally, we provide preliminary evidence of miR-365b-3p and miR-7-1-3p being overexpressed, and miR-6507-5p, miR-487b-3p, and miR-654-3p being downregulated in DCIS relative to normal breast tissue. We also identified a miRNA miR-766-3p that was overexpressed in early-stage IDCs. The overexpression of miR-301a-3p in DCIS and IDC was confirmed in 32 independent breast cancer tissue samples. Results:: Higher expression of miR-301a-3p is associated with poor overall survival in The Can-cer Genome Atlas Breast Cancer (TCGA-BRCA) dataset, indicating that it may be associated with DCIS at high risk of progressing to IDC and warrants deeper investigation. Conclusion:: We also analyzed competing endogenous networks associated with differentially expressed miRNAs and identified LRRC75A-AS1 and MAGI2-AS3 as lncRNAs that potentially play an important role in early-stage breast cancers.